Keywords
Contact tracing apps, epidemiology, methodology, systematic review, COVID-19
This article is included in the Emerging Diseases and Outbreaks gateway.
This article is included in the Coronavirus collection.
Contact tracing apps, epidemiology, methodology, systematic review, COVID-19
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak has dominated worldwide news and scientific research throughout 2020. Since the outbreak in Wuhan (People’s Republic of China) in early December 2019, reducing transmission of SARS-CoV-2 has been a worldwide priority. Digital technology could be applied for efficient contact tracing. Contact tracing applications (CTAs) are able to identify individuals who have recently been in close contact with infected individuals (and may have acquired infection as a consequence). After identification, the contact person can be instructed to go in self-quarantine, preventing further transmission and spread of the virus.
A substantial amount of research on CTAs for SARS-CoV-2 has been performed since the start of the pandemic. Summarizing all evidence, including results from research that has not yet, or is currently undergoing peer-review, is warranted to provide an overview of what is known regarding CTA effectiveness. Research that has not yet undergone peer-review is often published by authors through so-called preprint databases. However, identifying these articles, extracting data, and drawing conclusions can be a challenge, as this requires knowledge on epidemiology, mathematical modelling, systematically appraising evidence, and summarizing that evidence.
A few overviews of evidence on effectiveness of CTAs have been published in recent time. Anglemyer et al. provided an overview of study characteristics and quality appraisal of studies on effectiveness of CTAs and other digital contact tracing technologies.1 However, their data were based on both SARS-CoV-2 infections and other infections (e.g., Ebola), and lacked a quantitative effectiveness measure of CTAs on clinically relevant outcomes. Other systematic reviews focused only on user experience in using a CTA for SARS-CoV-2,2 barriers and challenges for implementation,3 or only studied manual as opposed to digital contact tracing.4 One systematic review did look into studies on automated and semi-automated CTAs for SARS-CoV-2, but lacked reporting on CTA effectiveness on total number of infections, and hospitalization or mortality rates.5
In this systematic review, we evaluate all (empirical and model based) studies addressing effectiveness of CTAs for SARS-CoV-2 on relevant, i.e., epidemiological and clinical, outcomes. We provide descriptive characteristics, critical appraisal, and a narrative summary of evidence of included studies. This paper is an update of the original systematic review on this topic (doi: 10.1136/bmjopen-2021-050519; published July 2021). An update is warranted, as additional empirical and model-based studies assessing the effectiveness of CTAs have been disseminated since publication of the original systematic review. In particular, empirical studies assessing effects of CTAs on quarantine rates, infections, and mortality rate, have been published in recent time, and have been included in this updated systematic review.
Reporting in this paper follows guidance from the PRISMA statement. The checklist and all supplementary files are available via the Open Science Framework repository.36
The Bern COVID-19 Open Access Project (COAP) database was used for identification of relevant research. The COAP database is comprised of research from EMBASE (OVID), MEDLINE (PubMed), BioRxiv and MedRxiv databases, specifically focused on SARS-CoV-2. On June 9th 2021 the COAP database was searched for scientific literature evaluating the effectiveness of CTAs for SARS-CoV-2 on epidemiological and clinical outcomes. The complete search strategy, as well as background information on the COAP database provided by Bern University, are provided in the Extended data: Supplementary File 1.
Empirical (both observational and experimental) and model-based studies evaluating effectiveness of CTAs for SARS-CoV-2 were eligible for inclusion. Peer-reviewed publications as well as preprint papers were considered.
CTAs were considered when they provided feedback about potential recent exposure to an infected individual, based on proximity measurements (e.g., Bluetooth or GPS). Feedback should be provided directly to the individual through a CTA, although other feedback mechanisms, such as personal devices (e.g., a smartwatch), were also considered. National emergency warning systems using SMS were also included, provided they used proximity data to inform individuals.
All epidemiologically or clinically relevant outcomes that were used to quantify the impact of CTAs were considered, which include but are not limited to: quarantine rate, reproduction number (R), total number of infections, hospitalization rate, and mortality rate related to SARS-CoV-2. Studies investigating other relevant outcomes, such as prevention of outbreaks, a second infection wave, or flattening the curve, were also included. Studies solely assessing (determinants affecting) adoption rate of CTAs (i.e., the proportion of citizens using, and following recommendations provided by, the CTA), temporal change in incidence SARS-CoV-2, or other non-epidemiological or clinical outcomes were excluded.
Studies identified in the search were first screened independently on title and abstract by two reviewers. Relevant studies were included for full text screening, and further selection of articles was performed by two independent reviewers. Any discrepancies were discussed and resolved. When consensus was not reached, a third reviewer was consulted to provide the final judgement.
Risk of bias was independently assessed by two researchers using separate checklists for empirical and model-based studies. Discrepancies between researchers were discussed and a final verdict was provided by a third reviewer if consensus was not reached. Empirical studies were appraised using a formal scoring method based on the Critical Appraisal Skills Programme (CASP) and Cochrane’s Effective Practice and Organisation of Care (EPOC) checklists6,7 (Extended data: Supplementary File 2). Risk of bias in model-based research was evaluated by assessing use of empirical input data for the model, number of scenarios analyzed, and transparency of model reporting (Extended data: Supplementary File 3). Information on competing interests and funding were also collected for both empirical and model-based studies.
Data extraction was performed manually by one reviewer and checked by a second reviewer. Descriptive characteristics on type of research, i.e., empirical or model-based, sample size, (simulated) time horizon, study population, CTA properties and intervention, comparator, and epidemiological and clinical outcomes studied, were extracted from all included studies.
Specifically for model-based research, model characteristics (i.e., type of model and distributions used) and values used for important model parameters were collected. Furthermore, CTA specific properties were extracted, such as the method of contact tracing used by these apps. Forward tracing CTAs can only detect the ‘offspring’, i.e., individuals the index case has infected, of an infected individual. Bidirectional tracing CTAs also detect the ‘parents’, i.e., the individual that infected the index case of an infected individual. Models were considered to use bidirectional (as opposed to forward) tracing when, after the index case is detected and registered, all contacts within a period of at least the incubation time are identified, such that the parent of the index case could be found.
Another CTA specific property included the use of 1-step-tracing or sequential tracing. When a CTA-identified individual could only notify their contacts after testing positive themselves, this was considered 1-step-contact tracing. When notified contacts could subsequently also notify their own contacts, creating a cascade, even before that individual has shown symptoms or received a positive test result for SARS-CoV-2, this was considered sequential tracing.
The most important findings regarding effectiveness of CTAs for SARS-CoV-2 on epidemiological and clinical outcomes were extracted, synthesized, and reported narratively. These outcomes were pooled quantitatively whenever it was feasible to do so.
A total of 5,123 potential studies were identified by the search. After selection based on title and abstract, 4,941 articles were excluded. Full texts of the 182 remaining studies were assessed, after which 27 articles were included for critical appraisal and data extraction (Extended data: Supplementary File 4). The 155 excluded studies with their reasons for exclusion are summarized in Extended data: Supplementary File 5.
A total of 27 primary studies were included, of which five were empirical observational (non-randomized) studies, and 22 were model-based studies (Tables 1 and 2).
Study | Country (1st author) | Study type | Sample size/simulations | Time horizon | Population | Specific setting(s) | Intervention | Comparison | Outcome(s) |
---|---|---|---|---|---|---|---|---|---|
Abueg 2021 | USA | Modelling | 10 simulations | 5.5 months | General (working) population (three Washington state counties) | - | CTA (Bluetooth) with quarantine (not for household contacts) | MCT | - Fraction in quarantine - Cumulative incidence SARS-CoV-2 - Peak # hospitalized - Cumulative and daily mortality rate |
Almagor 2020 | United Kingdom | Modelling | N/R | 300 days | General population (Glasgow) | Various* | CTA (Bluetooth) | No CTA & no testing | - Daily prevalence of SARS-CoV-2 - Peak prevalence of SARS-CoV-2 |
Ballouz 2020 | Switzerland | Empirical | 654 individuals | 10 days | Infectees & close contacts (Zurich) | - | SwissCovid CTA (Bluetooth) | CTA non-users | - Duration of going in to quarantine |
Barrat 2021 | France, Japan | Modelling | 10,000 simulations | 4 weeks | General working/studying population | - Students - Office workers | CTA (Bluetooth) combined with MCT | MCT alone | - Fraction of quarantine events - Fraction of individuals recovered from SARS-CoV-2 |
Bradshaw 2020 | Germany | Modelling | 500 or 1000 simulations | 52 weeks or 10,000 cases | General population | - | CTA (Bluetooth) with quarantine | - MCT - Current practice | - R - Outbreak control |
Bulchandani 2021 | USA | Modelling | 4000 simulations | N/R | Susceptible population | - | CTA (not specified) with quarantine | - | - R - Outbreak control |
Cencetti 2021 | Italy | Modelling | 20 simulations | 50 days | General population | - University - High school - Workplace | CTA (Bluetooth) with quarantine | - | - R - Outbreak control |
Chen 2020 | Taiwan | Empirical | 3000 individuals | 40 days | General population (Taiwan) | - | Public Warning System SMS (GPS) with quarantine & monitoring | Current practice | - Respiratory syndrome - Pneumonia |
Currie 2020 | Australia | Modelling | Not reported | 12 months | General population (Australia) | - | COVIDSafe CTA (Bluetooth) with quarantine | No CTA | - Outbreak control - Cumulative incidence SARS-CoV-2 |
Elmokashfi 2021 | Norway | Modelling | N/R | 18 days | General population (Norway) | - | Smittestopp CTA (Bluetooth) | MCT | - R - Outbreak control |
Ferrari 2020 | Italy | Modelling | 5500 simulations | 400 days | General population (Italy) | - | CTA (not specified) with quarantine & monitoring | - | - R/Outbreak control - Cumulative incidence SARS-CoV-2 - Mortality |
Ferretti 2020 | China | Modelling | 40 simulations | 20 days | General population (China) | - Home - Train - Work | CTA (Bluetooth) with quarantine | MCT | R |
Fyles 2021 | UK | Modelling | 100 simulations | 2 years | General population | - Within-household - Between-household | CTA (not specified) with quarantine and vigilance | No contact tracing | - Growth rate - Probability of extinction pandemic |
Grimm 2021 | Germany | Modelling | N/R | 500 days | General population (Germany) | - High severe infection risk - Low severe infection risk | CTA (not specified) with quarantine | - No intervention - Social distancing (uniform & group-specific) | - Cumulative incidence SARS-CoV-2 - # of days ICU capacity exceeded - Mortality |
Guttal 2020 (preprint) | N/R | Modelling | N/R | 150-200 days | General population | - | CTA (Bluetooth) with quarantine | - | Cumulative incidence SARS-CoV-2 |
Kendall 2020 | United Kingdom | Empirical | Population-size Isle of Wight & UK | <2 months | General population (Isle of Wight and UK) | - | NHS CTA (version 1) (Bluetooth) with social distancing | - | - R - Cumulative incidence SARS-CoV-2 |
Kretzschmar 2020 | Netherlands | Modelling | 1,000 simulations | N/R | General population | - Close cont. - Casual cont. | CTA (Bluetooth) with quarantine | Social distancing without CTA | R |
Kucharski 2020 | United Kingdom | Modelling | 25,000 simulations | N/R | General population (UK) | - Household - Work - School | CTA (Bluetooth) with quarantine | - | - R - Outbreak control |
Kurita 2020 | Japan | Modelling | N/R | 5 months | General population (Japan) | - | COCOA CTA (Bluetooth) with quarantine | - | R |
Menges 2021 | Switzerland | Empirical | 537 individuals | 60 days | General population (Zurich) | - | SwissCovid CTA (Bluetooth) with quarantine | MCT | - Number of SARS-CoV-2 infections - Number of quarantine events |
Nuzzo 2020 | USA | Modelling | N/R | 400 days | Susceptible individuals | - | CTA (GPS,WiFi, and/or Bluetooth) with quarantine | Shelter in place | - Cumulative incidence SARS-CoV-2 - Mortality |
Pandl 2021 | Germany | Modelling | 30 simulations | Until end of outbreak | Not specified | - Household - Workplace - School - Supermarket | CTA (Bluetooth) with quarantine | No contact tracing | - Number of SARS-CoV-2 infections - Duration of outbreak - Susceptible fraction after outbreak - Quarantine time |
Pollmann 2021 | Germany | Modelling | 100 simulations | 500 days | General population | - | CTA (Bluetooth) with quarantine | - | - R - Outbreak control - Cumulative incidence SARS-CoV-2 |
Rusu 2021 (preprint) | United Kingdom | Modelling | 750 simulations | 140 days | Not specified | - | CTA (not specified) | MCT | - Number of SARS-CoV-2 infections - Outbreak peak value - R - Hospitalizations - Mortality |
Scott 2020 | Australia | Modelling | N/R | 3.5 months | Susceptible population (Victoria) | Various** | COVIDSafe CTA (Bluetooth) with quarantine | - | Cumulative incidence SARS-CoV-2 |
Shamil 2021 | Bangladesh | Modelling | N/R | 120 days | Susceptible population (Ford County & New York City) | - Healthcare w. - Students - Service hold. - Unemployed | CTA (not specified) with quarantine | - Lockdown - Extra personal protection | - R - Cumulative incidence SARS-CoV-2 |
Wymant 2021 | United Kingdom | Empirical | 16.5 million individuals | 3 months | General population (England & Wales) | - | National Health Service (NHS) CTA (Bluetooth) | Manually traced close contacts | - SARS-CoV-2 cases averted - SARS-CoV-2 cases reduced - SARS-CoV-2-related deaths averted |
Two of the 27 studies were published preprints, meaning they had not (yet) gone through the peer review process at the time of data extraction.8,9 Included studies focused predominantly on the general population, although some analyzed the effectiveness of CTAs for specific populations such as hospital personnel, or school children.10–19 Especially in model-based studies, results were often presented graphically. Consequently, the effectiveness of CTAs on epidemiological and clinical outcomes was only partly, or not at all, reported in key numerical figures.
The model-based studies typically assessed the effectiveness of CTAs by simulating one or more scenarios based on certain baseline or input values (e.g., proportion of asymptomatic infections). Table 3 provides an overview of characteristics and the most important input parameters used in models of the 22 included studies. Ten of the 22 model-based studies evaluated forward tracing CTAs,12,13,15,16,18–23 nine studies analyzed bidirectional tracing CTA,8–11,14,24–27 and three used an alternative or unclear method.17,28,29 Ten studies used a CTA with sequential tracing.8–11,14,17,24–27 Nine of these also used bidirectional CTAs, which are more effective than forward tracing CTAs in reducing R, but require quarantining many more contact persons. This is especially the case when a significant number of infections come from asymptomatic individuals (i.e., transmission from a case who does not (yet) have symptoms), who are unaware they have SARS-CoV-2.25
Study | Model-related properties | Contact- and tracing related properties | Disease-related properties | Modifiable properties | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Modeltype | Input parameter properties | Tracing direction | # of sequential generations | Adoption rate CTA | R | Incubation time | Infectious period | Probability of disease transmission | Delay symptom onset and testing | Delay testing and feedback app | Quarantine effectiveness | |
Abueg 2021 | Agent-based | Estimates generation time distribution | Bidirectional | >1 generation | 0;15;30;45;60;75% | 5.02;5.18; 5.221 | 5.42 days | 6 days | Fitted, variable in settings | 1 day | 1 day | 80;90% |
Almagor 2020 | Agent-based | Estimates generation time distribution | Bidirectional | >1 generation | 0;20;40;60;80% | 1.5;2.8 | 5.1 days | 8-20 days (age-dependent) | Variable between settings | 1-3 days | 1 day | 70% |
Barrat 2021 | Agent based | Estimates generation time distribution | Bidirectional | >1 generation | 0-100% | 3.0 | 5.2 days | 3.8 days | Variable between settings | 0-2 days2 | 0-2 days2 | 60;100% |
Bradshaw 2020 | Branching-process | Distributions | Bidirectional | Infinite generations | 53;80% | 2.5 | 5.5 days | Fitted to curve | Fitted to curve | 1 days | 0 days | 90% |
Bulchandani 2020 | Branching-process | Estimates generation time distribution | Bidirectional | 3-infinite generations | 0-100% | 3.0 | N/A3 | N/A | N/R | N/A4 | 0 days | 100% |
Cencetti 2020 | Continuous weighted temporal network | Distributions | Forward | 1 generation | 60;80;100% | 1.2;1.5;2.0 | Fitted to curve | Fitted to curve | Fitted to curve, value not specified | 2 days | 0 days | 0-100% |
Currie 2020 | ODE compartmental | Estimates generation time distribution | Forward | 1 generation | 0;27;40;61;80% | 2.5 | 2.0 days | 11 days | N/R | 3 days | N/R | 90% |
Elmokashfi 20215 | PDE compartmental | Distributions | Forward | 1 generation | 0-100% | 1.5;2.7 | 5.5 days | 12 days | Fitted to curve | 1.6 days | 4;24;48 hours | 50;70;90% |
Ferrari 2020 | ODE compartmental | Estimates generation time distribution | Forward | 1 generation | 0;25;50;75% | 1.5 | 5.1 days | 10 days | 10% | 2 days | N/R | 90% |
Ferretti 2020 | PDE compartmental | Distributions | Forward | 1 generation | 0-100% | 2.0 | 5.5 days | 12 days | Fitted to curve | 1.6 days | 0 days | 0-100% |
Fyles 20216 | Agent-based/Branching process | Estimates generation time distribution | Bidirectional | >1 generation | 0-50% | Fitted to curve | 4.84 days | 12 days (Weibull distribution) | Fitted to curve | 2.62 days | 0 days | 50-100% 100% in households |
Grimm 2020 | ODE compartmental | Estimates generation time distribution | Forward | 1 generation | 20-80% | 2.2;3.0 | 5.0 days | 10;12.5;14;20 days | N/R | N/R | N/R | 100%7 |
Guttal 2020 | Individual-based network | Estimates generation time distribution | Bidirectional | >1 generation | 100% | 3.0;4.0 | N/A | 20 days | 0.2% | N/R | N/R | 100% |
Kretzschmar 2020 | Branching-process | Distributions | Forward | 1 generation | 20;40;60; 80;100% | 2.5 | 6.4 days | 10 days | 2-12% | 0 days | 0 days | 0;20;40; 60;80;100% |
Kucharski 2020 | Individual-based network | Distributions | Forward | 1 generation | 53% | 2.6 | 5.0 days | 5 days | 20% in HH 6% outs. HH 50% less for asymptomatic | 0 days | 0 days | 90% |
Kurita 2020 | ODE compartmental | Estimates generation time distribution | N/R | 1 generation | 0;10;20;30;40;50; 60;70;80;90; 100% | 1.5 | 6.6 days | N/R | N/R | 2 days | 0 days | N/R |
Nuzzo 2020 | ODE compartmental | Estimates generation time distribution | N/A7 | N/A8 | 0;10;20;30;40;50; 60;70;80;90% | 3.02 | 5.1 days | N/R | Fitted to curve | N/R | N/R | 100% |
Pandl 2021 | Agent-based | Estimates generation time distribution | N/R | >1 generation | 0;20;40;60;80;100% | 2.79 | 6.83 days (triangular distribution) | 9 days | Fitted based on proximity of individuals | N/R | N/R | 100% |
Pollmann 2020 | ODE compartmental | Estimates generation time distribution | Bidirectional | >1 generation | 60;75;90;100% | 2.0-3.0-4.0 | 4.0;7.4 days | 10 days | 7%9 | 0;2;4;6 days | N/R | 100% |
Rusu 2021 | Multi-site mean-field | Estimates generation time distribution | Bidirectional | >1 generation | 0-100% | 3.18 | 5.2 days | 2.3 days | Fitted | N/R | N/R | 100% |
Scott 2020 | Agent-based | Distributions | Forward | 1 generation | 0-50% | Fitted to curve | 4.6 days | 8-14 days | Fitted to curve | 1 day | 1 day | 0% in HH 80-100% in other settings |
Shamil 2020 | Agent-based | Distributions | Forward | 1 generation | 60;75% | Fitted to curve | 6.0 days | 10 days | N/R | 0 days | 0 days | 100% |
The percentage of CTA adoption was varied in almost all studies, allowing for assessment of the impact of CTAs on epidemiological and clinical outcomes. Average incubation time, i.e., the mean time between infection and symptom onset of SARS-CoV-2, was estimated to be 5 to 6 days for SARS-CoV-2, which was used by the majority of model-based studies.9–11,13–16,19,21,22,24,25,27,29 The proportion of asymptomatic SARS-CoV-2 infections, used as input parameter in model-based studies, was estimated at 20% to 50% based on empirical data,12,13,15,22 but could vary between 18% to 86%.15 The baseline R value chosen in the model-based studies varied between 1.212 and 5.22.24
Furthermore, superspreaders (i.e., individuals that infect numerous other individuals, and consequently have a high individual R) were discussed in context of the SARS-CoV-2 pandemic. Tracing these superspreaders and their contacts using CTAs was more effective compared to manual contact tracing (MCT).21 Hence, it is warranted to use bidirectional CTAs to trace these superspreaders, and advise them to immediately enter quarantine on identification.16,30
Risk of bias of the five empirical studies was judged to be unclear for two,31,32 and high for three33–35 (Table 4). Confounding variables (such as smoking, work status, and income) were insufficiently taken into account for the three high risk studies, which was due to the explanatory nature of these observational empirical studies. In four out of five studies it was also unclear how missing (outcome) data were dealt with.
Study | Confounding? | Selection bias: participants? | Selection bias: missing data? | Information bias: misclassification of the intervention? | Information bias: misclassification of the outcome? | Other concerns? | Overall risk of bias |
---|---|---|---|---|---|---|---|
Ballouz 2020 | No* | No | No | No | Unclear | No competing interests External funding | Unclear |
Chen 2020 | Yes** | No | Unclear | No | Unclear | No competing interests External funding | High |
Kendall 2020 | Yes | No | Unclear | No | No | Competing interests not reported Funding not reported | High |
Menges 2021 | Yes | No | Unclear | No | Unclear | Competing interests External funding | High |
Wymant 2021 | No | No | Unclear | No | N/A*** | Competing interests External funding | Unclear |
Most model-based research was judged to have a low risk of bias (Table 5). Seven of the 22 studies had a high risk of bias due to the lack of use of empirical distributions for variables, the limited number of scenarios analyzed, and insufficient transparency regarding reporting of the model.10,11,14,17,19,28,29
Study | Were empirical distributions used for a varying infectiousness since time of infection? | Were various different scenarios evaluated for important model assumptions and parameter values? | Were models reported transparently? (i.e., no black box) | Other concerns? | Overall risk of bias |
---|---|---|---|---|---|
Abueg 2021 | Yes | Yes | Yes | Competing interest Funding not reported | Low |
Almagor 2020 | No | Yes | Yes | No competing interest Funding not reported | High |
Barrat 2021 | No | Yes | Yes | No competing interest External funding | High |
Bradshaw 2020 | Yes | Yes | Yes | Competing interests not reported External funding | Low |
Bulchandani 2020 | No | Yes | Yes | Competing interests not reported Funding not reported | Low |
Cencetti 2020 | Yes | Yes | Yes | No competing interests No financial interests | Low |
Currie 2020 | Yes | Yes | Yes | No competing interests Funding not reported | Low |
Elmokashfi 2021 | Yes | Yes | Yes | Competing interest not reported Funding not reported | Low |
Ferrari 2020 | No | Yes | Yes | Competing interests Funding not reported | Low |
Ferretti 2020 | Yes | Yes | Yes | No competing interests External funding, though no influence of funder on study conception and execution | Low |
Fyles 2021 | Yes | Yes | Yes | No competing interest External funding | High |
Grimm 2020 | No | Yes | Yes | Competing interests not reported External funding | Low |
Guttal 2020 | Yes | Yes | Yes | Competing interests not reported Funding not reported | Low |
Kretzschmar 2020 | Yes | Yes | Yes | No competing interests External funding | Low |
Kucharski 2020 | Yes | Yes | Yes | No competing interests External funding, though no influence of funder on study results | Low |
Kurita 2020 | No | No* | Unclear | Competing interests not reported Funding not reported Type of model used unclear | High |
Nuzzo 2020 | No | No* | Yes | Competing interest Funding not reported | High |
Pandl 2021 | No | Yes | Yes | No competing interests External funding | High |
Pollmann 2020 | Yes | Yes | Yes | Competing interests not reported Funding not reported | Low |
Rusu 2021 | Yes | Yes | Yes | Competing interest not reported Funding not reported | Low |
Scott 2020 | Yes | Yes | Yes | No competing interests External funding | Low |
Shamil 2020 | No | Yes | Unclear | No competing interests No external funding | High |
Evidence from empirical studies
Five empirical comparative observational studies assessed the effectiveness of CTAs.31–35 Two studies used empirical data to derive downstream consequences of CTAs using model-based extensions.32,35
Ballouz et al. studied the time of going to quarantine for users and non-users of the SwissCovid.31 Results showed that close contacts of index cases that used a CTA went into quarantine sooner compared to non-users of the CTA [Hazard Ratio (HR) 1.5 (95% confidence interval (CI) 1.2–2.0)]. A second study looking at the SwissCovid CTA used empirical data on the number of authorization codes entered by SARS-CoV-2 positive individuals to model the downstream consequences on quarantine recommendations sent out and the increase in number of positively tested contacts.35 From their model-based assessment they found that at most 1.7-5.1% additional cases of SARS-CoV-2 could have been detected by CTA in addition to MCT.
Another study investigated the introduction and adoption of a ‘Test and Trace’ app by 34,000 individuals living on the Isle of Wight (UK) and compared the estimated value of R in that region to that in the general UK population.34 The CTA marked individuals as positive based on self-reporting of symptoms. Individuals that came in contact with an individual marked as positive were provided with social distancing advice. The study found that R reduced from 1.3 to 0.5 after implementation of the CTA. Within 2 to 3 weeks after implementation, incidence of SARS-CoV-2 diagnoses declined by around 90%.34
A fourth study looked at the effectiveness of a text warning system used in 627,386 individuals who came in contact with an exposed population, and compared this cohort to the general population of Taiwan who did not use such a warning system.20 They showed a reduction in incidence of respiratory syndrome from 19.23 to 16.87 per 1000 individuals. They also showed a reduction in pneumonia incidence from 3.81 to 2.36 per 1000 individuals.20
Finally, Wymant et al. studied the effect of introduction of the NHS COVID-19 CTA on number of cases averted and mortality rate.32 Usage and notification data from 16.5 million users in the UK were used to estimate downstream consequences of NHS CTA use. They used a model-based and a statistical analysis approach and found that respectively 284,000 (95% of simulations ranged between 108,000–450,000) cases, or 594,000 (95% CI 317,000–914,000) cases, could be averted through use of the NHS CTA, relating to 15% or 31% of the total number of cases. Subsequently they determined that 4,200 (95% simulation range 1,600–6,600) deaths, or 8,700 (95% CI 4,700–13,500) deaths could be prevented based on the model-based and statistical approach, respectively. This corresponds to 13% or 27% of the total number of deaths. Approximately one case was averted for each case consenting to notification of their contacts. For every percentage point increase in CTA uptake, the number of cases could be reduced by 0.8% or 2.3% based on the model-based and statistical approach respectively.
Evidence from model-based studies
Effect on R
Effectiveness of a 1-step-contact tracing in reducing R can be approached using the following formula:
Here, Rc is the reproduction number when a CTA is used, R is the reproduction number without the use of a CTA, p is the proportion of the population using the CTA, and f is the combination of other factors that affect effectiveness of notification by the CTA. Such factors include, but are not limited to, delay between CTA notification and testing, delay between testing and test result, delay between reception of test result and entry of that result in the CTA, compliance to interventions (e.g., self-quarantine), and the proportion of infections that occur pre- or asymptomatically. Note that p occurs as a quadratic term, which reflects the fact that both infector and infectee have to use the CTA for the transmission to get traced.
Thirteen of the 22 model-based studies assessed the effect of CTAs on reduction of R.9,12–14,16,19,21–23,25–28 CTAs were able to control an ongoing outbreak or epidemic through quicker and more efficient feedback of a positive test result, and by notifying close contacts of a positively tested individual.13,23,25 This speed and efficiency were not feasible using traditional MCT.13 New outbreaks could be controlled (i.e., Rc<1.0) by CTAs, by combining them with quarantine or self-isolation interventions, under the condition that hygiene and social distancing measures are maintained.12,16,22,28 CTAs were able to reduce R by 0.3 more than traditional MCT, provided that feedback about contact with a positively tested individual is given to all contacts of the index case of the preceding 7 days.25 Another model-based study reported that a CTA with 20% adoption rate reduces R by 17.6% compared to no contact tracing, whereas traditional MCT reduced R by 2.5% compared to no contact tracing.23 This study also demonstrated that a CTA is able to reduce the R further, even when social distancing has already reduced R to 1.2. In this situation, R can be reduced further by 30% to 0.8 when CTA adoption rate is 80%.23 Another model-based study determined that 60% adoption rate of a CTA could result in an R below 1.0.19 In one study, adoption rate of 53% resulted in a 47% reduction in R when the complete household of an individual with a positive test result is advised to be quarantined.16 The last study looking at effect of CTA on R showed that only at 60% adoption rate of the app a significant beneficial effect on R would become apparent.27 When R is high (e.g., 3.0), and a considerable proportion of individuals is asymptomatic (e.g., 40% of all infections), CTAs need to be combined with other interventions (such as social distancing and random testing) to be able to lower the R below 1.0.27 Potential for CTAs to reduce R is not only dependent on the adoption rate of the app, but also on (effectiveness of) various other factors in the downstream cascade after a positive notification. These include, but are not limited to, the delay between positive notification and testing,27 and delay between receiving a positive test result,21 and the proportion of users sharing that result through the CTA. One study found that the percentage of preventable infections by one individual strongly depends on the time delay between CTA notification and the ability to be tested.23 When there was no delay (i.e., 0 days) 79.9% of infections could be prevented, compared to 41.8% and 4.9% for 3 and 7 day delay, respectively.
Effect on total number of infections
Twelve of the 22 model-based studies assessed the effect of CTAs on reducing the total number of infections.8–10,15,17–20,22,24,27,29 Two studies indicated that the success of CTAs in reducing the total number of infections could only be ensured with a high adoption rate of that app.12,18 Some plateau effect at 60% adoption rate was observed by one study.24 Another study showed that with a high CTA adoption rate of 75%, there would be no more new infections occurring within three months after implementation.19 It was found that adequate hygiene and social distancing measures are needed to enable CTAs to reduce the total number of infections.12,15,20,22 Especially in areas where there is low compliance to social distancing, a sufficiently high adoption rate of a CTA is essential to maintain control of an outbreak.15
The peak number of new infections can, according to one study, be reduced by half with a 50% adoption rate of a CTA,22 whereas another study showed that this could be achieved with an adoption rate as low as 20%.29 Another study demonstrated that at 27% CTA adoption rate, a quarter of all new infections can be prevented.20 However, according to another study that used a similar adoption rate, the number of infections would stabilize, but the epidemic would be maintained by core groups in densely populated areas.22 There may be a period of time of more than two months between implementation of interventions (such as CTAs) and the effect of that implementation on the total number of SARS-CoV-2 infections.18
Effect on number of hospitalizations
Two of the 22 model-based studies assessed the effect of CTAs on the number of hospitalizations due to SARS-CoV-2 infection. One study found that the peak number of hospitalizations reduced up to 46-78% for a 75% CTA adoption rate.24 Another found that peak height of number of hospitalizations could be reduced by at least 50% for a CTA adoption rate of 60% and over.9 A German study did look into the effect of a CTA on the number of days that intensive care unit (ICU) capacity was exceeded.15 They found in their simulations that – based on the German population, and assuming an ICU capacity of 24.000 beds – a CTA adoption rate of 20% would prevent exceedance of ICU capacity at any point in time. In contrast, if no contact tracing (either manual or digital) would be used, ICU capacity would be exceeded on a quarter of days.
Effect on mortality rate
Five of the 22 model-based studies assessed the effect of CTAs on mortality rate.9,15,22,24,29 One study demonstrated that a high adoption rate (80%) of a CTA would result in an 85% reduction in mortality rate, over a period of 500 days.15 Another study found that a low CTA adoption rate (25%) is associated with a 10% decrease in mortality rate, an average adoption rate (50%) with 25% decrease, and a high adoption rate (75%) with 40-60% decrease.22 For the latter 75% CTA adoption rate, slightly higher rates (56-67%) were observed in another study.24 Other evidence showed that at 40% adoption rate, during the peak of an outbreak, a reduction in number of deaths by 97% could be achieved.29 Ruse et al demonstrated that mortality rate could be reduced by at least 50% for CTA adoption rates of 60% and over, provided testing rates were sufficient.9
Empirical evidence regarding the effectiveness of using CTAs for detection of SARS-CoV-2 is still limited. Currently, no randomized studies have been performed, and only five observational (non-randomized) studies were identified in this systematic review. Two of these assessed the effects of CTA use on the number of infections and mortality, though only through modelling based on empirically observed CTA usage data. Although, in general, benefits of using CTAs for detection of SARS-CoV-2 were observed, all studies were deemed to have a high or unclear risk of bias, due to the potential presence of uncontrolled confounding factors, unclear handling of missing data, or both.
Despite these concerns for validity, the results of the empirical studies were in accordance with the (in general high quality) 22 included model-based studies assessing effectiveness of CTAs. These model-based studies showed that CTAs can be effective and a valuable addition to MCT. CTA use consistently resulted in a lower R, lower total number of infections, and lower mortality rate. These reductions were already observed at relatively low adoption rates (e.g., 20%), though higher adoption rates of CTAs clearly resulted in greater impact. Shortening delays between CTA notification and diagnostic testing may increase its effectiveness.
This systematic review assesses key features, quality, and main clinical and epidemiological outcomes of a set of studies, both empirical and model-based, on effectiveness of CTAs for SARS-CoV-2. To our knowledge, no such systematic review, assessing these specific properties, has been published. Methodological quality of empirical studies was assessed using standardized quality assessment tools. No such tool was available in literature for model-based studies, and as such a set of key features used in systematic reviews on similar topics was used. This set was validated by experts in mathematical modelling of infectious diseases.
To fully appreciate the findings from this systematic review, some considerations should be taken into account. First, the studies found through the literature search do not include studies published after the search date. Although this seems trivial, it should be noted that studies on SARS-CoV-2 are published at a rapid basis in various online repositories. Between the initial publication of this systematic review and its update on average 432 papers were published per day on SARS-CoV-2 in the COAP database. We cannot ensure that all studies on the effectiveness of CTAs for SARS-CoV-2 have been identified, however we believe that the set of included studies that we have identified is a representative sample.
Furthermore, effectiveness of CTAs for SARS-CoV-2 described in model-based studies is complex. Numerous input variables used in the models interact with one another, and consequently affect effectiveness of, for example, adoption rate of CTAs on clinical or epidemiological outcomes. Summarizing these findings into the general effectiveness is difficult, and will always suffer from simplification of a system of complex interactions. Though we feel that providing (conditional) findings from these studies will help provide some general insight in the impact CTAs may have on clinical and epidemiological outcomes for SARS-CoV-2.
Current evidence on the effectiveness of CTAs for SARS-CoV-2 is predominantly based on modelling studies, which indicate that there is potential in beneficially affecting key clinical and epidemiological outcomes. What this update of our original systematic review adds, is additional knowledge from empirical studies that use modelling to assess downstream consequences of CTAs. Although these studies are valuable, they do not provide direct empirical evidence on relevant outcomes. High quality empirical evidence, either from experimental or methodologically sound comparative observational studies, is still needed to be able to draw more robust conclusions regarding effectiveness of CTAs for SARS-CoV-2.
This paper may be further updated in the future, depending on whether additional empirical research (RCTs or observational studies) on the effectiveness of CTAs for SARS-CoV-2 is published.
All data underlying the results are available as part of the article and no additional source data are required.
Open Science Framework: Supplementary files for Systematic review on Effectiveness of Contact tracing apps for COVID-19, https://doi.org/10.17605/OSF.IO/J5M7D.36
This project contains the following extended data:
Open Science Framework: PRISMA checklist for ‘Effectiveness of contact tracing apps for SARS-CoV-2: an updated systematic review’, https://doi.org/10.17605/OSF.IO/J5M7D.36
Data are available under the terms of the Creative Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).
This research was funded directly (no grant number) by the Dutch Ministry of Health, Welfare and Sport. Researchers involved in this study contributed to the study’s conception and execution independently from the funding agency, and as such it was in no way influenced by the funding agency.
Views | Downloads | |
---|---|---|
F1000Research | - | - |
PubMed Central
Data from PMC are received and updated monthly.
|
- | - |
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Partly
Is the statistical analysis and its interpretation appropriate?
Yes
Are the conclusions drawn adequately supported by the results presented in the review?
Partly
Competing Interests: No competing interests were disclosed.
Reviewer Expertise: Public health
Are the rationale for, and objectives of, the Systematic Review clearly stated?
Yes
Are sufficient details of the methods and analysis provided to allow replication by others?
Yes
Is the statistical analysis and its interpretation appropriate?
Not applicable
Are the conclusions drawn adequately supported by the results presented in the review?
Partly
References
1. Ballouz T, Menges D, Aschmann HE, Jung R, et al.: Individual-Level Evaluation of the Exposure Notification Cascade in the SwissCovid Digital Proximity Tracing App: Observational Study.JMIR Public Health Surveill. 2022; 8 (5): e35653 PubMed Abstract | Publisher Full TextCompeting Interests: No competing interests were disclosed.
Reviewer Expertise: Clinical infectious diseases, epidemiology (focus on contact tracing in COVID-19)
Alongside their report, reviewers assign a status to the article:
Invited Reviewers | ||
---|---|---|
1 | 2 | |
Version 1 12 May 22 |
read | read |
Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list:
Sign up for content alerts and receive a weekly or monthly email with all newly published articles
Already registered? Sign in
The email address should be the one you originally registered with F1000.
You registered with F1000 via Google, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Google account password, please click here.
You registered with F1000 via Facebook, so we cannot reset your password.
To sign in, please click here.
If you still need help with your Facebook account password, please click here.
If your email address is registered with us, we will email you instructions to reset your password.
If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance.
Comments on this article Comments (0)